194 related articles for article (PubMed ID: 37096142)
21. Case series of progressive familial intrahepatic cholestasis type 3: Characterization of variants in
Cheng J; Gong L; Mi X; Wu X; Zheng J; Yang W
Front Med (Lausanne); 2022; 9():962408. PubMed ID: 36569137
[TBL] [Abstract][Full Text] [Related]
22. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
[TBL] [Abstract][Full Text] [Related]
23. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis.
de Vree JM; Jacquemin E; Sturm E; Cresteil D; Bosma PJ; Aten J; Deleuze JF; Desrochers M; Burdelski M; Bernard O; Oude Elferink RP; Hadchouel M
Proc Natl Acad Sci U S A; 1998 Jan; 95(1):282-7. PubMed ID: 9419367
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles.
Ilyinskii PO; Roy CJ; LePrevost J; Rizzo GL; Kishimoto TK
Front Immunol; 2021; 12():637469. PubMed ID: 34113339
[TBL] [Abstract][Full Text] [Related]
25. Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
Stättermayer AF; Halilbasic E; Wrba F; Ferenci P; Trauner M
J Hepatol; 2020 Sep; 73(3):651-663. PubMed ID: 32376413
[TBL] [Abstract][Full Text] [Related]
26. Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents.
Ilyinskii PO; Roy C; Michaud A; Rizzo G; Capela T; Leung SS; Kishimoto TK
PNAS Nexus; 2023 Nov; 2(11):pgad394. PubMed ID: 38024395
[TBL] [Abstract][Full Text] [Related]
27. Hydrophilic bile acids prevent liver damage caused by lack of biliary phospholipid in
Wang R; Sheps JA; Liu L; Han J; Chen PSK; Lamontagne J; Wilson PD; Welch I; Borchers CH; Ling V
J Lipid Res; 2019 Jan; 60(1):85-97. PubMed ID: 30416103
[TBL] [Abstract][Full Text] [Related]
28. Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3.
Frider B; Castillo A; Gordo-Gilart R; Bruno A; Amante M; Alvarez L; Mathet V
Ann Hepatol; 2015; 14(5):745-51. PubMed ID: 26256905
[TBL] [Abstract][Full Text] [Related]
29. Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants.
Dröge C; Bonus M; Baumann U; Klindt C; Lainka E; Kathemann S; Brinkert F; Grabhorn E; Pfister ED; Wenning D; Fichtner A; Gotthardt DN; Weiss KH; McKiernan P; Puri RD; Verma IC; Kluge S; Gohlke H; Schmitt L; Kubitz R; Häussinger D; Keitel V
J Hepatol; 2017 Dec; 67(6):1253-1264. PubMed ID: 28733223
[TBL] [Abstract][Full Text] [Related]
30. Liver pathology in severe multidrug resistant 3 protein deficiency: a series of 10 pediatric cases.
Vij M; Safwan M; Shanmugam NP; Rela M
Ann Diagn Pathol; 2015 Oct; 19(5):277-82. PubMed ID: 26117383
[TBL] [Abstract][Full Text] [Related]
31. ABCB4 disease: Many faces of one gene deficiency.
Sticova E; Jirsa M
Ann Hepatol; 2020; 19(2):126-133. PubMed ID: 31759867
[TBL] [Abstract][Full Text] [Related]
32. Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Kishimoto TK
Front Immunol; 2020; 11():969. PubMed ID: 32508839
[TBL] [Abstract][Full Text] [Related]
33. ABCB4 Mutations in Adults Cause a Spectrum Cholestatic Disorder Histologically Distinct from Other Biliary Disease.
Sinha A; Bhuva M; Grant C; Gimson AE; Thompson E; Duckworth A; Davies SE; Aithal G; Griffiths WJ
Dig Dis Sci; 2022 Dec; 67(12):5551-5561. PubMed ID: 35288833
[TBL] [Abstract][Full Text] [Related]
34. Clinical and genetic characterization of pediatric patients with progressive familial intrahepatic cholestasis type 3 (PFIC3): identification of 14 novel ABCB4 variants and review of the literatures.
Chen R; Yang FX; Tan YF; Deng M; Li H; Xu Y; Ouyang WX; Song YZ
Orphanet J Rare Dis; 2022 Dec; 17(1):445. PubMed ID: 36550572
[TBL] [Abstract][Full Text] [Related]
35. Advances in familial and congenital cholestatic diseases. Clinical and diagnostic implications.
Colombo C; Okolicsanyi L; Strazzabosco M
Dig Liver Dis; 2000 Mar; 32(2):152-9. PubMed ID: 10975791
[TBL] [Abstract][Full Text] [Related]
36. Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes.
Gilkes JA; Bloom MD; Heldermon CD
Mol Genet Metab Rep; 2016 Mar; 6():48-54. PubMed ID: 27014573
[TBL] [Abstract][Full Text] [Related]
37. Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases.
Chen HL; Wu SH; Hsu SH; Liou BY; Chen HL; Chang MH
J Biomed Sci; 2018 Oct; 25(1):75. PubMed ID: 30367658
[TBL] [Abstract][Full Text] [Related]
38. Case Report: A rare case of young adult progressive familial intrahepatic cholestasis-type 3 with a novel heterozygous pathogenic variant of
Zhu H; Wang S; Li L; Geng W; Wan X; Hua R; Wang D; Gao P
Front Pediatr; 2022; 10():1012825. PubMed ID: 36330364
[TBL] [Abstract][Full Text] [Related]
39. ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression.
Degiorgio D; Crosignani A; Colombo C; Bordo D; Zuin M; Vassallo E; Syrén ML; Coviello DA; Battezzati PM
J Gastroenterol; 2016 Mar; 51(3):271-80. PubMed ID: 26324191
[TBL] [Abstract][Full Text] [Related]
40. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis.
De Vree JM; Ottenhoff R; Bosma PJ; Smith AJ; Aten J; Oude Elferink RP
Gastroenterology; 2000 Dec; 119(6):1720-30. PubMed ID: 11113093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
